SINGAPORE, Sept. 23, 2024 /PRNewswire/ -- Amber Group, a leading global digital asset company, today announced that its Dubai subsidiary, Amber Premium FZE, has secured an in-principle approval (IPA) for the Virtual Asset Service Provider (VASP) license from the Dubai Virtual Assets Regulatory Authority (VARA).
The in-principle approval allows Amber Premium FZE to offer a comprehensive suite of virtual asset services, including broker-dealer activities, lending and borrowing solutions, and management and investment services, all within the regulatory framework of the UAE. Serving as the company's regional headquarters, Amber Premium FZE will cater to both institutional clients and high-net-worth individuals in the region.
As the world's first specialized regulator for virtual assets, VARA is committed to fostering a responsible and innovative virtual asset ecosystem in Dubai. Its comprehensive regulatory framework, designed to protect investors and ensure market integrity, aligns with Amber Group's own commitment to security and compliance.
"We are proud to receive this in-principle approval, underscoring our dedication to responsible innovation within robust regulatory environments like Dubai's," said Michael Wu, CEO of Amber Group. "With our regional hub in Dubai, we look forward to expanding our premium virtual asset services and expertise across the Middle East, providing clients with tailored solutions backed by our deep global experience."
With a proven track record of compliance, Amber Group previously secured licenses from major financial centers worldwide, including a Major Payment Institution (MPI) license from the Monetary Authority of Singapore (MAS) and Type 1, 4, and 9 licenses from the Hong Kong Securities and Futures Commission through its subsidiaries.
About Amber Group
Amber Group is a global digital asset leader headquartered in Singapore. Since 2017, we've built full-stack solutions that bridge traditional finance and digital assets, offering end-to-end services including wealth management, asset management, market making, advisory, investing and infrastructure. Backed by top investors and with deep expertise in crypto and traditional markets, we leverage AI, blockchain and quantitative research to deliver personalized and cutting-edge solutions to help our global client base of HNW individuals, institutions, crypto funds, exchanges and projects optimize returns safely in any market conditions
For more information, please visit:
About VARA
Established in March 2022, following the effect of Law No.4 of 2022, VARA is the competent entity in charge of regulating, supervising, and overseeing VAs and VA Activities in all zones across the Emirate of Dubai, including Special Development Zones and Free Zones but excluding the Dubai International Financial Centre. VARA plays a central role in creating Dubai's advanced legal framework to protect investors and establish international standards for Virtual Asset industry governance, while supporting the vision for a borderless economy.
Learn more at: https://www.vara.ae/
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Amber Group's Dubai Subsidiary Secures In-Principle Approval for Virtual Asset Service Provider License from Dubai VARA
Late-breaking HRX data advance Field Medical's "instantaneous ablation" workflow and expand the clinical evidence for high-voltage focal PFA with the FieldForce™ PFA System
ATLANTA and CARLSBAD, Calif., Sept. 20, 2026 /PRNewswire/ -- Field Medical, Inc., advancing high-voltage focal pulsed field ablation (PFA) for complex arrhythmias, today announced publication of 12-month results from the first-in-human Field PULSE trial in JACC: Clinical Electrophysiology. The findings were presented simultaneously as a Late-Breaking Clinical Trial at HRX Live 2026.
Field Medical developed the FieldForce™ PFA System around a high-voltage focal PFA architecture designed first for the ventricle, where depth, stability and control are among the most difficult challenges in ablation. Field PULSE extends that work into the atrium and evaluates a subsecond point-by-point workflow Field Medical terms "instantaneous ablation." In this study, the approach was associated with procedural efficiency, durable pulmonary vein isolation (PVI) and flexibility beyond the pulmonary veins, without the need for prolonged catheter stability.
Key Findings:
- Procedural efficiency with subsecond focal PFA: 13-minute median elapsed PVI ablation time, with a fastest time of 7.7 minutes
- Durable PVI with the optimized waveform: 94.2% per-vein durability reflecting progressive improvement with waveform evolution
- Flexible focal ablation: 49% of patients received non-PV ablation for additional atrial targets
- No primary safety events were observed
- 80% freedom from atrial arrhythmias at 12 months with the optimized waveform
"Field PULSE demonstrates the feasibility of truly instantaneous focal PFA," said Vivek Reddy, M.D., co-principal investigator, lead author and electrophysiologist at Mount Sinai Health System. "Delivering the full application in less than 200 milliseconds reduces the need for prolonged catheter stability while preserving the flexibility of point-by-point ablation. The procedural efficiency, safety and pulmonary vein durability observed with the optimized waveform support continued clinical development of this approach."
The publication builds on Field Medical's peer-reviewed clinical work in ventricular tachycardia. Six-month outcomes from the company's first-in-human VCAS trial were published in Circulation in 2025. Field PULSE now adds first-in-human, peer-reviewed atrial data evaluating the same high-voltage focal PFA architecture through a distinct focal workflow in a different cardiac substrate.
"We designed FieldForce to solve some of the hardest problems in focal cardiac ablation, beginning in the ventricle," said Mark A. Turco, M.D., president and chief executive officer of Field Medical. "Field PULSE demonstrates that the same high-voltage focal PFA architecture can support an 'instantaneous ablation' workflow in the atrium. This growing body of evidence reinforces the range of the platform: depth and focal control in the ventricle, speed and precision in the atrium, and the versatility to address very different cardiac substrates through a familiar point-by-point approach. These results add important clinical evidence as we continue to advance our differentiated PFA platform."
The study, "High-Voltage Focal PFA Catheter for 'Instant' Point-By-Point Ablation: The First-In-Human FIELD-PULSE Trial to Treat AF," was published online in JACC: Clinical Electrophysiology concurrent with the HRX presentation. DOI: 10.1016/j.jacep.2026.09.001.
About Field Medical®, Inc.
Field Medical is a clinical-stage medical technology company committed to advancing pulsed field ablation (PFA) solutions for complex cardiac arrhythmias. The company was founded by Steven Mickelsen, M.D., CTO, a pioneer and global thought leader in PFA whose work has helped shape the evolution of the field. The FieldForce PFA System integrates a focal catheter design with proprietary FieldBending™ energy designed to safely deliver efficient, precise ablation with the goal of improving outcomes in ventricular and atrial arrhythmia treatment. In 2024, Field Medical earned Breakthrough Device Designation and gained entry into the FDA TAP Pilot Program for its ventricular tachycardia indication. In October 2025, the VCAS trial was published in Circulation.
For more information, visit fieldmedicalinc.com and follow us on LinkedIn and YouTube.
The FieldForce™ PFA System is an investigational device and is limited by federal (or United States) law to investigational use.
Media Contact
Holly Windler
619.929.1275
media@fieldmedicalinc.com
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
JACC: Clinical Electrophysiology Publishes 12-Month Outcomes from Field Medical's First-in-Human Field PULSE Trial: 94.2% Per-Vein PVI Durability with Optimized Waveform
